Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07559396 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease
A Phase 1 study, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT07559396 is a Phase 1 study that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 16 participants.
The verdict
NCT07559396, a Phase 1 study, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study will be conducted to assess the safety and pharmacokinetics of INCB123667 when administered orally to adult participants with severe renal impairment or end stage renal disease.
Interventions
- DRUG INCB123667
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2026-05-29 |
| Est. Completion | 2027-01-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07559396
The ClinicalTrials.gov registry entry for NCT07559396 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INCB123667 is the first listed.
NCT07559396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07559396 about?
NCT07559396 is a clinical study titled "A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease". This study will be conducted to assess the safety and pharmacokinetics of INCB123667 when administered orally to adult participants with severe renal impairment or end stage renal disease.
What is the current status of trial NCT07559396?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2026-05-29. Estimated completion is 2027-01-04.
What interventions are being tested in trial NCT07559396?
The interventions under investigation include: INCB123667 (DRUG).
Who is sponsoring clinical trial NCT07559396?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.